Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622609 · ClinicalTrials.gov registry record · Phase 1
Anti-MAG First Administration to Human
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00622609 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 46 participants.
The verdict
NCT00622609, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke.
Interventions
- DRUG Placebo
- DRUG GSK249320A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-08-01 |
| Est. Completion | 2009-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622609
The ClinicalTrials.gov registry entry for NCT00622609 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00622609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622609 about?
NCT00622609 is a clinical study titled "Anti-MAG First Administration to Human". GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal inju...
What is the current status of trial NCT00622609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2007-08-01. Estimated completion is 2009-04-09.
What interventions are being tested in trial NCT00622609?
The interventions under investigation include: Placebo (DRUG), GSK249320A (DRUG).
Who is sponsoring clinical trial NCT00622609?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.